Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901) - PubMed
4 hours ago
- #Prostate Cancer
- #PSMA-PET
- #Overall Survival
- The ENZA-p sub-study evaluated 3-month PSMA total tumor volume (PSMA-TTV) as a prognostic biomarker for overall survival in metastatic castrate-resistant prostate cancer patients treated with enzalutamide ± [177Lu]Lu-PSMA-617.
- An increase in PSMA-TTV at 3 months was associated with significantly shorter overall survival (HR 2.52) and lower 2-year survival (30% vs 67%) compared to a decrease.
- Residual 3-month PSMA-TTV higher than the median (103 ml) was associated with worse overall survival (HR 3.76) and lower 2-year survival (34% vs 76%), independent of treatment arm and PSA response.
- The findings suggest that interim PSMA-PET response criteria, based on PSMA-TTV, have prognostic value for overall survival and warrant further prospective validation.